Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Protein-Drug Binding: Determination Methods01:22

Protein-Drug Binding: Determination Methods

Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AP2B1, a protein involved in endocytic trafficking, is associated with congenital heart defects when mutated.

Genes & diseasesยท2026
Same author

15-LOX-catalytic bias towards ether-(alkenyl)-ETE-PEs oxidation bestows selectivity of PRO-ferroptotic cell death signaling.

Nature communicationsยท2026
Same author

Structural and molecular determinants of glutamate transporter allosteric modulators.

Molecular pharmacologyยท2026
Same author

Small Molecule Activators of Protein Phosphatase 2A Exert Global Stabilizing Effects on the Scaffold PR65.

JACS Auยท2026
Same author

Challenging Ureteroscopy in Complex Anatomy: A Case Report.

Cureusยท2026
Same author

Cryo-electron microscopy structure of a zinc uptake ABC transporter.

Structure (London, England : 1993)ยท2026

Related Experiment Video

Updated: Jun 25, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

DruGUI 2.0: mapping protein druggability with probe-based molecular dynamics.

Carlos Ventura1,2, Ji Young Lee1, Anthony T Bogetti1,3

  • 1Laufer Center for Physical and Quantitative Biology, Stony Brook University, Stony Brook, NY 11794, United States.

Bioinformatics (Oxford, England)
|June 24, 2026
PubMed
Summary

DruGUI 2.0 is a new drug discovery tool that identifies druggable protein sites and potential drug molecules. It accounts for protein flexibility and aids in building pharmacophore models for drug development.

More Related Videos

Mapping Dysfunctional Protein-Protein Interactions in Disease
09:39

Mapping Dysfunctional Protein-Protein Interactions in Disease

Published on: October 24, 2025

Related Experiment Videos

Last Updated: Jun 25, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Mapping Dysfunctional Protein-Protein Interactions in Disease
09:39

Mapping Dysfunctional Protein-Protein Interactions in Disease

Published on: October 24, 2025

Area of Science:

  • Computational chemistry
  • Structural biology
  • Drug discovery

Background:

  • ProDy is an open-source Python package for analyzing protein sequences, structures, and dynamics.
  • DruGUI 2.0 builds upon the ProDy API to offer advanced drug discovery functionalities.

Purpose of the Study:

  • To introduce DruGUI 2.0, a novel computational tool for assessing protein druggability.
  • To facilitate the identification of allosteric and orthosteric binding sites on proteins.
  • To enable the prediction of small molecules with high binding affinity to target proteins.

Main Methods:

  • Simulations in explicit solvent, with optional membrane inclusion.
  • Utilizing an expanded library of drug-like fragments as probe molecules.
  • Analyzing probe-protein interactions to characterize druggable sites and estimate binding affinities.

Main Results:

  • DruGUI 2.0 successfully identifies druggable sites beyond traditional orthosteric regions.
  • The tool predicts small molecules (probes) with high affinity for identified sites.
  • Pharmacophore models and relative binding affinities can be estimated based on probe composition and position.

Conclusions:

  • DruGUI 2.0 enhances drug discovery by enabling flexible protein site assessment.
  • The tool integrates seamlessly with the ProDy ecosystem, offering advanced visualization.
  • Case studies demonstrate DruGUI 2.0's applicability to both soluble and membrane proteins.